Drug Profile
Alpha-antitrypsin - Arriva/Hyland Immuno/Protease Sciences
Alternative Names: Alpha-1 antitrypsin - Arriva/Hyland Immuno/Protease Sciences; Alpha-1 proteinase inhibitor - Arriva/Hyland Immuno/Protease Sciences; Inhaled rAAT - Arriva/Hyland Immuno/Protease Sciences; rAAT - Arriva/Hyland Immuno/Protease SciencesLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Protease Sciences
- Developer Arriva Pharmaceuticals; Hyland Immuno
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action HIV protease inhibitors; Leucocyte elastase inhibitors; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alpha 1-antitrypsin deficiency; Chronic obstructive pulmonary disease; Cystic fibrosis; HIV infections; Otitis media; Viral hepatitis
Most Recent Events
- 08 Feb 2008 Phase II development for alpha 1-antitrypsin deficiency is ongoing
- 31 Oct 2006 Discontinued - Preclinical for Cystic fibrosis in USA (Inhalation)
- 31 Oct 2006 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)